| 12/10/22 | 07:00:06 | 12 Oct 2022 | | First regional distribution agreement |
| 30/09/22 | 17:30:04 | 30 Sept 2022 | | Issue of Equity |
| 30/09/22 | 17:30:04 | 30 Sept 2022 | | Holding(s) in Company |
| 29/09/22 | 07:00:12 | 29 Sept 2022 | | Interim Results |
| 29/09/22 | 07:00:08 | 29 Sept 2022 | | Positive headline results from ovarian study |
| 28/09/22 | 07:00:12 | 28 Sept 2022 | | Study using Parsortix in head and neck cancer |
| 13/09/22 | 07:00:12 | 13 Sept 2022 | | New poster presented at ASCP Meeting |
| 12/09/22 | 07:30:47 | 12 Sept 2022 | | Novel assay predicts malignancy in pelvic mass |
| 01/09/22 | 07:00:09 | 1 Sept 2022 | | Notice of Interim Results and Webcast |
| 28/07/22 | 07:00:18 | 28 Jul 2022 | | Novel insight into metastasis in NSCLC patients |
| 20/07/22 | 14:33:25 | 20 Jul 2022 | | Holding(s) in Company |
| 20/07/22 | 07:00:09 | 20 Jul 2022 | | NEW STUDY OF PARSORTIX SYSTEM IN NSCLC |
| 19/07/22 | 10:00:03 | 19 Jul 2022 | | Director/PDMR Shareholding |
| 15/07/22 | 07:00:05 | 15 Jul 2022 | | Results of Capital Raise |
| 14/07/22 | 17:24:48 | 14 Jul 2022 | | Retail Offer via PrimaryBid |
| 14/07/22 | 17:23:27 | 14 Jul 2022 | | Proposed Placing and Retail Offer |
| 08/07/22 | 17:30:01 | 8 Jul 2022 | | Issue of Equity |
| 29/06/22 | 16:35:40 | 29 Jun 2022 | | Result of 2022 Annual General Meeting |
| 27/06/22 | 07:00:08 | 27 Jun 2022 | | Spread of breast cancer accelerates during sleep |
| 23/06/22 | 18:24:58 | 23 Jun 2022 | | Issue of Equity |
| 22/06/22 | 07:00:06 | 22 Jun 2022 | | Secured contract from pharma services customer |
| 16/06/22 | 07:00:09 | 16 Jun 2022 | | Predicting immunotherapy response in SCLC |
| 14/06/22 | 07:00:07 | 14 Jun 2022 | | Potential role of invasive cellular protrusions |
| 30/05/22 | 07:00:07 | 30 May 2022 | | Partnership with major United States urology group |
| 27/05/22 | 07:00:07 | 27 May 2022 | | Molecular characterisation of CTCs |
| 25/05/22 | 16:35:20 | 25 May 2022 | | Price Monitoring Extension |
| 25/05/22 | 12:30:35 | 25 May 2022 | | ANGLE receives FDA clearance for Parsortix |
| 20/05/22 | 07:00:08 | 20 May 2022 | | Prostate Cancer UK funds new study using Parsortix |
| 28/04/22 | 07:00:12 | 28 Apr 2022 | | Preliminary Results |
| 20/04/22 | 07:00:05 | 20 Apr 2022 | | Notice of Preliminary Results and Webcast |
| 14/04/22 | 07:00:06 | 14 Apr 2022 | | Poster on Parsortix system presented at AACR 2022 |
| 01/04/22 | 07:00:10 | 1 Apr 2022 | | Identifying drug targets in cancer metastasis |
| 29/03/22 | 07:00:11 | 29 Mar 2022 | | Rapid information on patient response to therapies |
| 25/03/22 | 07:00:07 | 25 Mar 2022 | | Identifying therapeutic targets in TNBC patients |
| 15/03/22 | 07:00:07 | 15 Mar 2022 | | Update on laboratory accreditation |
| 09/03/22 | 16:41:33 | 9 Mar 2022 | | Second Price Monitoring Extn |
| 09/03/22 | 16:36:10 | 9 Mar 2022 | | Price Monitoring Extension |
| 02/03/22 | 18:29:01 | 2 Mar 2022 | | Holding(s) in Company |
| 18/02/22 | 17:13:01 | 18 Feb 2022 | | Issue of Equity |
| 21/01/22 | 07:00:16 | 21 Jan 2022 | | Potential in immunotherapy treatment selection |
| 17/01/22 | 07:00:08 | 17 Jan 2022 | | Concordance of Parsortix with tissue biopsy |
| 13/01/22 | 07:00:05 | 13 Jan 2022 | | Update on lab accreditation and ovarian study |
| 10/01/22 | 07:00:10 | 10 Jan 2022 | | Insight into drug resistance in NSCLC |
| 22/12/21 | 18:29:15 | 22 Dec 2021 | | Issue of Equity |
| 01/12/21 | 18:11:04 | 1 Dec 2021 | | Issue of Equity |
| 01/12/21 | 07:00:10 | 1 Dec 2021 | | Parsortix in RNA analysis of CTCs as tool in NSCLC |
| 26/11/21 | 17:33:54 | 26 Nov 2021 | | Issue of Equity |
| 17/11/21 | 10:32:30 | 17 Nov 2021 | | Issue of Equity |
| 15/11/21 | 07:00:07 | 15 Nov 2021 | | Issue of LTIP Options and Share Options |
| 15/11/21 | 07:00:06 | 15 Nov 2021 | | Appointment of Chief Medical Officer |
